StockData
Upstream Bio, Inc. logo

Upstream Bio, Inc. (UPB) stock

UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$2.08−0.02 (-0.95%)

Close on Nov 18, 2026Market cap $113.92MP/E –Yield –

Upstream Bio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Upstream Bio's revenue for the twelve months ending Sep 30, 2026 was $2.87M, up 2.5% year over year. For fiscal 2025 it was $2.85M, up 20.4% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.85M+20.4%
FY2024Dec 31, 2024$2.37M-0.4%
FY2023Dec 31, 2023$2.38M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$395.00K-42.2%
Q2 FY2026Jun 30, 2026$773.00K-17.5%
Q1 FY2026Mar 31, 2026$1.03M+82.7%
Q4 FY2025Dec 31, 2025$668.00K+9.0%
Q3 FY2025Sep 30, 2025$683.00K+12.5%
Q2 FY2025Jun 30, 2025$937.00K+83.7%
Q1 FY2025Mar 31, 2025$566.00K-11.6%
Q4 FY2024Dec 31, 2024$613.00K+36.2%
Q3 FY2024Sep 30, 2024$607.00K-2.3%
Q2 FY2024Jun 30, 2024$510.00K–
Q1 FY2024Mar 31, 2024$640.00K–
Q4 FY2023Dec 31, 2023$450.00K–
Q3 FY2023Sep 30, 2023$621.00K–

More Upstream Bio figures

See a number that looks wrong?